Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve Injury
Open Access
- 1 April 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anesthesiology
- Vol. 108 (4), 722-734
- https://doi.org/10.1097/aln.0b013e318167af74
Abstract
Background Cannabinoids induce analgesia by acting on cannabinoid receptor (CBR) types 1 and/or 2. However, central nervous system side effects and antinociceptive tolerance from CBR1 limit their clinical use. CBR2 exist on spinal glia and perivascular cells, suggesting an immunoregulatory role of these receptors in the central nervous system. Previously, the authors showed that spinal CBR2 activation reduces paw incision hypersensitivity and glial activation. This study tested whether CBR2 are expressed in glia and whether their activation would induce antinociception, glial inhibition, central side effects, and antinociceptive tolerance in a neuropathic rodent pain model. Methods Rats underwent L5 spinal nerve transection or sham surgery, and CBR2 expression and cell localization were assessed by immunohistochemistry. Animals received intrathecal injections of CBR agonists and antagonists, and mechanical withdrawal thresholds and behavioral side effects were assessed. Results Peripheral nerve transection induced hypersensitivity, increased expression of CR3/CD11b and CBR2, and reduced ED2/CD163 expression in the spinal cord. The CBR2 were localized to microglia and perivascular cells. Intrathecal JWH015 reduced peripheral nerve injury hypersensitivity and CR3/CD11b expression and increased ED2/CD163 expression in a dose-dependent fashion. These effects were prevented by intrathecal administration of the CBR2 antagonist (AM630) but not the CBR1 antagonist (AM281). JWH015 did not cause behavioral side effects. Chronic intrathecal JWH015 treatment did not induce antinociceptive tolerance. Conclusions These data indicate that intrathecal CBR2 agonists may provide analgesia by modulating the spinal immune response and microglial function in chronic pain conditions without inducing tolerance and neurologic side effects.Keywords
This publication has 56 references indexed in Scilit:
- Extracellular Signal-Regulated Kinase-Regulated Microglia–Neuron Signaling by Prostaglandin E2Contributes to Pain after Spinal Cord InjuryJournal of Neuroscience, 2007
- Depletion of endogenous spinal 5-HT attenuates the behavioural hypersensitivity to mechanical and cooling stimuli induced by spinal nerve ligationPain, 2006
- Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in BrainAnnals of the New York Academy of Sciences, 2006
- Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal hornFEBS Letters, 2006
- Identification and Functional Characterization of Brainstem Cannabinoid CB 2 ReceptorsScience, 2005
- Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain modelsEuropean Journal of Neuroscience, 2003
- CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?Current Opinion in Pharmacology, 2003
- Cannabinoid CB1 Receptor Expression in Rat Spinal CordMolecular and Cellular Neuroscience, 2000
- Prolonged apparent half-life of Δ1-tetrahydrocannabinol in plasma of chronic marijuana usersJournal of Pharmacy and Pharmacology, 1988
- A Monoclonal Antibody to a Novel Differentiation Antigen on Human Macrophages Associated with the Down-Regulatory Phase of the Inflammatory ProcessPathobiology, 1987